Charlie Gourley, PhD, MBChB, chair and honorary consultant in Medical Oncology at Edinburgh Cancer Research Centre in the United Kingdom, discuses olaparib (Lynparza), which was recently investigated in a phase II Study 19 trial versus placebo as a maintenance therapy for patients with relapsed platinum-sensitive serous ovarian cancer.

The drug really works, says Gourley. The study was designed to look at progression-free survival (PFS), and, unequivocally, it clearly showed that this drug improved PFS, he says.  

There is also a potential improvement in overall survival (OS), but that is yet to be determined.

Oncologists really need to be checking the 

 status of their patients, and then if they have a mutation, they should think about the potential of giving them olaparib.

Charlie Gourley, PhD, MBChB

Articles

Dr. Charlie Gourley on Olaparib Maintenance in Ovarian Cancer